No specific information is available on the effects or treatment of Olmetec D overdose. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Management depends upon the time since ingestion and the severity of the symptoms. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Serum electrolytes and creatinine should be monitored frequently. If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly.
The most likely manifestations of olmesartan medoxomil overdose are expected to be hypotension and tachycardia; bradycardia might also occur. Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloraemia) and dehydration resulting from excessive diuresis. The most common signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasm and/or accentuate cardiac arrhythmias associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic medicinal products.
No information is available regarding the dialysability of olmesartan or hydrochlorothiazide.
Renal impairment.
Refractory hypokalaemia, hypercalcaemia, hyponatraemia and symptomatic hyperuricaemia.
Moderate and severe hepatic impairment, cholestasis and biliary obstructive disorders.
2nd and 3rd trimester of pregnancy.
The concomitant use of Olmetec D with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m2).
Not applicable.
The most commonly reported adverse reactions during treatment with Olmetec D 40 mg/12.5 mg and 40 mg/25 mg are headache (2.9%), dizziness (1.9%) and fatigue (1.0%).
Hydrochlorothiazide may cause or exacerbate volume depletion which may lead to electrolyte imbalance.
The safety of Olmetec D 40 mg/12.5 mg and 40 mg/25 mg was investigated in clinical trials in 3709 patients receiving olmesartan medoxomil in combination with hydrochlorothiazide.
Further adverse reactions reported with the fixed dose combination of olmesartan medoxomil and hydrochlorothiazide in the lower dose strengths 20 mg/12.5 mg and 20 mg/25 mg may be potential adverse reactions with Olmetec D 40 mg/12.5 mg and 40 mg/25 mg.
Adverse reactions from Olmetec D in clinical trials, post-authorisation safety studies and spontaneous reporting are summarised in the below table as well as adverse reactions from the individual components olmesartan medoxomil and hydrochlorothiazide based on the known safety profile of these substances.
The following terminologies have been used in order to classify the occurrence of adverse reactions: very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1000 to <1/100); rare (>1/10000 to <1/1000); very rare (<1/10000), not known (cannot be estimated from the available data).
MedDRA System Organ Class | Adverse reactions | Frequency | ||
| Olmetec D | Olmesartan | HCTZ | ||
| Infections and infestations | Sialadenitis | Rare | ||
| Blood and lymphatic system disorders | Aplastic anaemia | Rare | ||
| Bone marrow depression | Rare | |||
| Haemolytic anaemia | Rare | |||
| Leukopenia | Rare | |||
| Neutropenia/ Agranulocytosis | Rare | |||
| Thrombocytopenia | Uncommon | Rare | ||
| Immune system disorders | Anaphylactic reactions | Uncommon | Uncommon | |
| Metabolism and nutrition disorders | Anorexia | Uncommon | ||
| Glykosuria | Common | |||
| Hypercalcaemia | Common | |||
| Hypercholesterolaemia | Uncommon | Very common | ||
| Hyperglycaemia | Common | |||
| Hyperkalaemia | Rare | |||
| Hypertriglyceridaemia | Uncommon | Common | Very common | |
| Hyperuricaemia | Uncommon | Common | Very common | |
| Hypochloraemia | Common | |||
| Hypochloraemic alcalosis | Very rare | |||
| Hypokaliaemia | Common | |||
| Hypomagnesaemia | Common | |||
| Hyponatriaemia | Common | |||
| Hyperamylasaemia | Common | |||
| Psychiatric disorders | Apathy | Rare | ||
| Depression | Rare | |||
| Restlessness | Rare | |||
| Sleep disturbances | Rare | |||
| Nervous system disorders | Confusional state | Common | ||
| Convulsions | Rare | |||
| Disturbances in consciousness (such as loss of consciousness) | Rare | |||
| Dizziness/light-headedness | Common | Common | Common | |
| Headache | Common | Common | Rare | |
| Loss of appetite | Uncommon | |||
| Paraesthesia | Rare | |||
| Postural dizziness | Uncommon | |||
| Somnolence | Uncommon | |||
| Syncope | Uncommon | |||
| Eye disorders | Lacrimation decreased | Rare | ||
| Transient blurred vision | Rare | |||
| Worsening of pre-existing myopia | Uncommon | |||
| Acute myopia, acute angle-closure glaucoma | Not known | |||
| Xanthopsia | Rare | |||
| Ear and labyrinth disorders | Vertigo | Uncommon | Uncommon | Rare |
| Cardiac disorders | Angina pectoris | Uncommon | ||
| Cardiac arrhythmias | Rare | |||
| Palpitations | Uncommon | |||
| Vascular disorders | Embolism | Rare | ||
| Hypotension | Uncommon | Rare | ||
| Necrotising angiitis (vasculitis, cutaneous vasculitis) | Rare | |||
| Orthostatic hypotension | Uncommon | Uncommon | ||
| Thrombosis | Rare | |||
| Respiratory, thoracic and mediastinal disorders | Bronchitis | Common | ||
| Cough | Uncommon | Common | ||
| Dyspnoea | Rare | |||
| Interstitial pneumonia | Rare | |||
| Pharyngitis | Common | |||
| Pulmonary oedema | Rare | |||
| Respiratory distress | Uncommon | |||
| Rhinitis | Common | |||
| Gastrointestinal disorders | Abdominal pain | Uncommon | Common | Common |
| Constipation | Common | |||
| Diarrhoea | Uncommon | Common | Common | |
| Dyspepsia | Uncommon | Common | ||
| Gastric irritation | Common | |||
| Gastroenteritis | Common | |||
| Meteorism | Common | |||
| Nausea | Uncommon | Common | Common | |
| Pancreatitis | Rare | |||
| Paralytic ileus | Very rare | |||
| Vomiting | Uncommon | Uncommon | Common | |
| Sprue-like enteropathy | Very rare | |||
| Hepato-biliary disorders | Acute cholecystitis | Rare | ||
| Jaundice (intrahepatic cholestasic icterus) | Rare | |||
| Skin and subcutaneous tissue disorders | Allergic dermatitis | Uncommon | ||
| Anaphylactic skin reactions | Rare | |||
| Angioneurotic oedema | Rare | Rare | ||
| Cutaneous lupus erythematodes-like reactions | Rare | |||
| Eczema | Uncommon | |||
| Erythema | Uncommon | |||
| Exanthem | Uncommon | |||
| Photosensitivity reactions | Uncommon | |||
| Pruritus | Uncommon | Uncommon | ||
| Purpura | Uncommon | |||
| Rash | Uncommon | Uncommon | Uncommon | |
| Reactivation of cutaneous lupus erythematodes | Rare | |||
| Toxic epidermal necrolysis | Rare | |||
| Urticaria | Rare | Uncommon | Uncommon | |
| Musculoskeletal and connective tissue disorders | Arthralgia | Uncommon | ||
| Arthritis | Common | |||
| Back pain | Uncommon | Common | ||
| Muscle spasm | Uncommon | Rare | ||
| Muscular weakness | Rare | |||
| Myalgia | Uncommon | Uncommon | ||
| Pain in extremity | Uncommon | |||
| Paresis | Rare | |||
| Skeletal pain | Common | |||
| Renal and urinary disorders | Acute renal failure | Rare | Rare | |
| Haematuria | Uncommon | Common | ||
| Interstitial nephritis | Rare | |||
| Renal insufficiency | Rare | |||
| Renal dysfunction | Rare | |||
| Urinary tract infection | Common | |||
| Reproductive system and breast disorders | Erectile dysfunction | Uncommon | Uncommon | |
| General disorders and administration site conditions | Asthenia | Common | Uncommon | |
| Chest pain | Common | Common | ||
| Face oedema | Uncommon | |||
| Fatigue | Common | Common | ||
| Fever | Rare | |||
| Influenza-like symptoms | Common | |||
| Lethargy | Rare | |||
| Malaise | Rare | Uncommon | ||
| Pain | Common | |||
| Peripheral oedema | Common | Common | ||
| Weakness | Uncommon | |||
| Investigations | Alanine aminotransferase increased | Uncommon | ||
| Aspartate aminotransferase increased | Uncommon | |||
| Blood calcium increased | Uncommon | |||
| Blood creatinine increased | Uncommon | Rare | Common | |
| Blood creatine phosphokinase increased | Common | |||
| Blood glucose increased | Uncommon | |||
| Blood haematocrit decreased | Rare | |||
| Blood haemoglobin decreased | Rare | |||
| Blood lipids increased | Uncommon | |||
| Blood potassium decreased | Uncommon | |||
| Blood potassium increased | Uncommon | |||
| Blood urea increased | Uncommon | Common | Common | |
| Blood urea nitrogen increased | Rare | |||
| Blood uric acid increased | Rare | |||
| Gamma glutamyl transferase increased | Uncommon | |||
| Hepatic enzymes increased | Common |
Single cases of rhabdomyolysis have been reported in temporal association with the intake of angiotensin II receptor blockers.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
The toxic potential of olmesartan medoxomil/hydrochlorothiazide combinations was evaluated in repeated dose oral toxicity studies for up to six months in rats and dogs.
As for each of the individual substances and other medicinal products in this class, the main toxicological target organ of the combination was the kidney. The combination of olmesartan medoxomil/hydrochlorothiazide induced functional renal changes (increases in serum urea nitrogen and in serum creatinine). High dosages caused tubular degeneration and regeneration in the kidneys of rats and dogs, probably via a change in renal haemodynamics (reduced renal perfusion resulting from hypotension with tubular hypoxia and tubular cell degeneration). In addition the olmesartan medoxomil/ hydrochlorothiazide combination caused a decrease in red blood cell parameters (erythrocytes, haemoglobin and haematocrit) and a reduction in heart weight in rats.
These effects have also been observed for other AT1 receptor antagonists and for ACE inhibitors and they seem to have been induced by the pharmacological action of high dosages of olmesartan medoxomil and seem to be not relevant to humans at the recommended therapeutic doses.
Genotoxicity studies using combined olmesartan medoxomil and hydrochlorothiazide as well as the individual components have not shown any signs of a clinically relevant genotoxic activity.
The carcinogenic potential of a combination of olmesartan medoxomil and hydrochlorothiazide was not investigated as there was no evidence of relevant carcinogenic effects for the two individual components under conditions of clinical use.
There was no evidence of teratogenicity in mice or rats treated with olmesartan medoxomil/hydrochlorothiazide combinations. As expected from this class of medicinal product, foetal toxicity was observed in rats, as evidenced by significantly reduced foetal body weights, when treated with olmesartan medoxomil/hydrochlorothiazide combinations during gestation.
Treatment of essential hypertension.
Olmetec D 40 mg/12.5 mg and 40 mg/25 mg fixed dose combinations are indicated in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil 40 mg alone.
Pharmacotherapeutic group: Angiotensin II antagonists and diuretics, ATC code: C09D A 08.
Mechanism of action / Pharmacodynamic effects
Olmetec D is a combination of an angiotensin II receptor antagonist, olmesartan medoxomil, and a thiazide diuretic, hydrochlorothiazide. The combination of these ingredients has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.
Once daily dosing with Olmetec D provides an effective and smooth reduction in blood pressure over the 24 hour dose interval.
Olmesartan medoxomil is an orally active, selective angiotensin II receptor (type AT1) antagonist. Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a significant role in the pathophysiology of hypertension. The effects of angiotensin II include vasoconstriction, stimulation of the synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by blocking its binding to the AT1 receptor in tissues including vascular smooth muscle and the adrenal gland. The action of olmesartan is independent of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors by olmesartan results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations.
In hypertension, olmesartan medoxomil causes a dose-dependent, long-lasting reduction in arterial blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during long-term treatment, or of rebound hypertension after abrupt cessation of therapy.
Once daily dosing with olmesartan medoxomil provides an effective and smooth reduction in blood pressure over the 24 hour dose interval. Once daily dosing produced similar decreases in blood pressure as twice daily dosing at the same total daily dose.
With continuous treatment, maximum reductions in blood pressure are achieved by 8 weeks after the initiation of therapy, although a substantial proportion of the blood pressure lowering effect is already observed after 2 weeks of treatment.
The effect of olmesartan medoxomil on mortality and morbidity is not yet known.
The Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study in 4447 patients with type 2 diabetes, normo-albuminuria and at least one additional cardiovascular risk factor, investigated whether treatment with olmesartan could delay the onset of microalbuminuria. During the median follow-up duration of 3.2 years, patients received either olmesartan or placebo in addition to other antihypertensive agents, except ACE inhibitors or ARBs.
For the primary endpoint, the study demonstrated a significant risk reduction in the time to onset of microalbuminuria, in favour of olmesartan. After adjustment for BP differences this risk reduction was no longer statistically significant. 8.2% (178 of 2160) of the patients in the olmesartan group and 9.8% (210 of 2139) in the placebo group developed microalbuminuria.
For the secondary endpoints, cardiovascular events occurred in 96 patients (4.3%) with olmesartan and in 94 patients (4.2%) with placebo. The incidence of cardiovascular mortality was higher with olmesartan compared to placebo treatment (15 patients (0.7%) vs. 3 patients (0.1%)), despite similar rates for non-fatal stroke (14 patients (0.6%) vs. 8 patients (0.4%)), non-fatal myocardial infarction (17 patients (0.8%) vs. 26 patients (1.2%)) and non-cardiovascular mortality (11 patients (0.5%) vs. 12 patients (0.5%)). Overall mortality with olmesartan was numerically increased (26 patients (1.2%) vs. 15 patients (0.7%)), which was mainly driven by a higher number of fatal cardiovascular events.
The Olmesartan Reducing Incidence of End-stage Renal Disease in Diabetic Nephropathy Trial (ORIENT) investigated the effects of olmesartan on renal and cardiovascular outcomes in 577 randomized Japanese and Chinese type 2 diabetic patients with overt nephropathy. During a median follow-up of 3.1 years, patients received either olmesartan or placebo in addition to other antihypertensive agents including ACE inhibitors.
The primary composite endpoint (time to first event of the doubling of serum creatinine, end-stage renal disease, all-cause death) occurred in 116 patients in the olmesartan group (41.1%) and 129 patients in the placebo group (45.4%) (HR 0.97 (95% CI 0.75 to 1.24); p=0.791). The composite secondary cardiovascular endpoint occurred in 40 olmesartan-treated patients (14.2%) and 53 placebo-treated patients (18.7%). This composite cardiovascular endpoint included cardiovascular death in 10 (3.5%) patients receiving olmesartan versus 3 (1.1%) receiving placebo, overall mortality 19 (6.7%) versus 20 (7.0%), non-fatal stroke 8 (2.8%) versus 11 (3.9%) and non-fatal myocardial infarction 3 (1.1%) versus 7 (2.5%), respectively.
Hydrochlorothiazide is a thiazide diuretic. The mechanism of the antihypertensive effect of thiazide diuretics is not fully known. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity and increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II and therefore coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with thiazide diuretics. With hydrochlorothiazide, onset of diuresis occurs at about 2 hours and peak effect occurs at about 4 hours post-dose, whilst the action persists for approximately 6-12 hours.
Epidemiological studies have shown that long-term treatment with hydrochlorothiazide monotherapy reduces the risk of cardiovascular mortality and morbidity.
Clinical efficacy and safety
The combination of olmesartan medoxomil and hydrochlorothiazide produces additive reductions in blood pressure which generally increase with the dose of each component.
In pooled placebo-controlled studies, administration of the 20 mg /12.5 mg and 20 mg /25 mg combinations of olmesartan medoxomil/hydrochlorothiazide resulted in mean placebo-subtracted systolic/diastolic blood pressure reductions at trough of 12/7 mmHg and 16/9 mmHg, respectively.
Administration of 12.5 mg and 25 mg hydrochlorothiazide in patients insufficiently controlled by olmesartan medoxomil 20 mg monotherapy gave additional reductions in 24-hour systolic/diastolic blood pressures measured by ambulatory blood pressure monitoring of 7/5 mmHg and 12/7 mmHg, respectively, compared with olmesartan medoxomil monotherapy. The additional mean systolic/diastolic blood pressure reductions at trough compared with baseline were 11/10 mmHg and 16/11 mmHg, respectively.
The effectiveness of olmesartan medoxomil /hydrochlorothiazide combination therapy was maintained over long-term (one-year) treatment. Withdrawal of olmesartan medoxomil therapy, with or without concomitant hydrochlorothiazide therapy, did not result in rebound hypertension.
The fixed combinations of olmesartan medoxomil and hydrochlorothiazide 40 mg/12.5 mg and 40 mg/25 mg were investigated in three clinical studies including 1482 hypertensive patients.
A double-blind study with essential hypertension evaluated the effectiveness of Olmetec D 40 mg/12.5 mg combination therapy versus olmesartan medoxomil monotherapy (Olmetec) 40 mg with mean sitting diastolic blood pressure reduction being the primary efficacy parameter. Systolic/diastolic blood pressure was reduced by 31.9/18.9 mmHg in the combination group as compared to 26.5/15.8 in the monotherapy group (p<0.0001) after 8 weeks of treatment.
In a double-blind but non-controlled second phase of this study, up-titration of non-responders from olmesartan medoxomil monotherapy (Olmetec) 40 mg to Olmetec D 40 mg/12.5 mg as well as from Olmetec D 40 mg/12.5 mg to Olmetec D 40 mg/25 mg resulted in a further relevant decrease in systolic/diastolic blood pressure, thus confirming that up-titration is a clinically meaningful way to improve blood pressure control.
A second double-blind, randomised, placebo-controlled study evaluated the effectiveness of adding hydrochlorothiazide to the treatment of patients not adequately controlled after 8 weeks of treatment with Olmetec 40 mg. Patients either continued on Olmetec 40 mg or received additional hydrochlorothiazide 12.5mg or 25mg respectively for another 8 weeks. A fourth group was randomised to receive Olmetec D 20 mg/12.5 mg.
Adding hydrochlorothiazide 12.5 mg or 25 mg resulted in a further reduction in systolic/diastolic blood pressure of 5.2/3.4 mmHg (p < 0.0001) and 7.4/5.3 mmHg (p < 0.0001) respectively as compared to the Olmetec 40 mg therapy alone.
A comparison between patients receiving Olmetec D 20 mg/12.5 mg and patients receiving 40 mg/12.5 mg showed a statistical significant difference in systolic blood pressure reduction of 2.6 mmHg in favour of the higher dose combination (p=0.0255) whereas for diastolic blood pressure reduction a difference of 0.9 mmHg was observed. Ambulatory blood pressure monitoring (ABPM) based on the mean changes on 24-hour, daytime and night-time diastolic and systolic blood pressure data confirmed the results of conventional blood pressure measures.
Another double-blind, randomised trial compared the effectiveness of a combination treatment with Olmetec D 20 mg/25 mg and Olmetec D 40 mg/25 mg in patients with inadequately controlled blood pressure after 8 weeks of treatment with Olmetec 40 mg.
After 8 weeks of combination therapy the systolic/diastolic blood pressure was significantly reduced as compared to baseline by 17.1/10.5 mmHg in the Olmetec D 20 mg/25 mg group and 17.4/11.2 mmHg in the Olmetec D 40 mg/25 mg group. The difference between both treatment groups was not statistically significant when using conventional blood pressure measurement, which might be explained by the known flat dose response effect of angiotensin II receptor antagonists such as Olmesartan medoxomil.
However, a clinically meaningful and statistically significant difference in favour of Olmetec D 40 mg/25 mg as compared to Olmetec D 20 mg/25 mg was observed in mean 24-hour, daytime and night-time ABPM on both systolic and diastolic blood pressure.
The antihypertensive effect of Olmetec D was similar irrespective of age, gender or diabetes status.
Other information:
Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.
ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.
These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.
ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.
Absorption and distribution
Olmesartan medoxomil:
Olmesartan medoxomil is a prodrug. It is rapidly converted to the pharmacologically active metabolite, olmesartan, by esterases in the gut mucosa and in portal blood during absorption from the gastrointestinal tract. No intact olmesartan medoxomil or intact side chain medoxomil moiety have been detected in plasma or excreta. The mean absolute bioavailability of olmesartan from a tablet formulation was 25.6%.
The mean peak plasma concentration (Cmax) of olmesartan is reached within about 2 hours after oral dosing with olmesartan medoxomil, and olmesartan plasma concentrations increase approximately linearly with increasing single oral doses up to about 80 mg.
Food had minimal effect on the bioavailability of olmesartan and therefore olmesartan medoxomil may be administered with or without food.
No clinically relevant gender-related differences in the pharmacokinetics of olmesartan have been observed.
Olmesartan is highly bound to plasma protein (99.7%), but the potential for clinically significant protein binding displacement interactions between olmesartan and other highly bound coadministered active substances is low (as confirmed by the lack of a clinically significant interaction between olmesartan medoxomil and warfarin). The binding of olmesartan to blood cells is negligible. The mean volume of distribution after intravenous dosing is low (16 - 29 L).
Hydrochlorothiazide:
Following oral administration of olmesartan medoxomil and hydrochlorothiazide in combination, the median time to peak concentrations of hydrochlorothiazide was 1.5 to 2 hours after dosing. Hydrochlorothiazide is 68 % protein bound in the plasma and its apparent volume of distribution is 0.83 - 1.14 L/kg.
Biotransformation and elimination
Olmesartan medoxomil:
Total plasma clearance of olmesartan was typically 1.3 L/h (CV, 19%) and was relatively slow compared to hepatic blood flow (ca 90 L/h). Following a single oral dose of 14C-labelled olmesartan medoxomil, 10 - 16% of the administered radioactivity was excreted in the urine (the vast majority within 24 hours of dose administration) and the remainder of the recovered radioactivity was excreted in the faeces. Based on the systemic availability of 25.6%, it can be calculated that absorbed olmesartan is cleared by both renal excretion (ca 40%) and hepato-biliary excretion (ca 60%). All recovered radioactivity was identified as olmesartan. No other significant metabolite was detected. Enterohepatic recycling of olmesartan is minimal. Since a large proportion of olmesartan is excreted via the biliary route, use in patients with biliary obstruction is contraindicated.
The terminal elimination half life of olmesartan varied between 10 and 15 hours after multiple oral dosing. Steady state was reached after the first few doses and no further accumulation was evident after 14 days of repeated dosing. Renal clearance was approximately 0.5 - 0.7 L/h and was independent of dose.
Hydrochlorothiazide:
Hydrochlorothiazide is not metabolised in man and is excreted almost entirely as unchanged active substance in urine. About 60 % of the oral dose is eliminated as unchanged active substance within 48 hours. Renal clearance is about 250 - 300 mL/min. The terminal elimination half-life of hydrochlorothiazide is 10 - 15 hours.
Olmetec D
The systemic availability of hydrochlorothiazide is reduced by about 20% when co-administered with olmesartan medoxomil, but this modest decrease is not of any clinical relevance. The kinetics of olmesartan are unaffected by the co-administration of hydrochlorothiazide.
Pharmacokinetics in special populations
Elderly (age 65 years or over):
In hypertensive patients, the olmesartan AUC at steady state was increased by ca 35% in elderly people (65 - 75 years old) and by ca 44% in very elderly people (> 75 years old) compared with the younger age group.
Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly people compared to young healthy volunteers.
Renal impairment:
In renally impaired patients, the olmesartan AUC at steady state increased by 62%, 82% and 179% in patients with mild, moderate and severe renal impairment, respectively, compared to healthy controls.
The maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatinine clearance of 30 - 60 mL/min) is 20 mg olmesartan medoxomil once daily. The use of olmesartan medoxomil in patients with severe renal impairment (creatinine clearance of < 30 mL/min) is not recommended.
The half-life of hydrochlorothiazide is prolonged in patients with impaired renal function.
Hepatic impairment:
After single oral administration, olmesartan AUC values were 6% and 65% higher in mildly and moderately hepatically impaired patients, respectively, than in their corresponding matched healthy controls. The unbound fraction of olmesartan at 2 hours post-dose in healthy subjects, in patients with mild hepatic impairment and in patients with moderate hepatic impairment was 0.26%, 0.34% and 0.41%, respectively. Following repeated dosing in patients with moderate hepatic impairment, olmesartan mean AUC was again about 65% higher than in matched healthy controls. Olmesartan mean Cmax values were similar in hepatically-impaired and healthy subjects.
In patients with moderate hepatic impairment, an initial dose of 10 mg olmesartan medoxomil once daily is recommended and the maximum dose should not exceed 20 mg once daily. Olmesartan medoxomil has not been evaluated in patients with severe hepatic impairment.
Hepatic impairment does not significantly influence the pharmacokinetics of hydrochlorothiazide.
Drug interactions
Bile acid sequestering agent colesevelam:
Concomitant administration of 40 mg olmesartan medoxomil and 3750 mg colesevelam hydrochloride in healthy subjects resulted in 28% reduction in Cmax and 39% reduction in AUC of olmesartan. Lesser effects, 4% and 15% reduction in Cmax and AUC respectively, were observed when olmesartan medoxomil was administered 4 hours prior to colesevelam hydrochloride. Elimination half life of olmesartan was reduced by 50 - 52% irrespectively of whether administered concomitantly or 4 hours prior to colesevelam hydrochloride.
Intravascular volume depletion:
Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of Olmetec D.
Other conditions with stimulation of the renin-angiotensin-aldosterone system:
In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure.
Renovascular hypertension:
There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system.
Renal impairment and kidney transplantation:
Olmetec D should not be used in patients with severe renal impairment (creatinine clearance < 30 mL/min).
The maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatinine clearance of 30 - 60 mL/min) is 20 mg olmesartan medoxomil once daily. However, in such patients Olmetec D 20 mg/12.5 mg and 20 mg/25 mg should be administered with caution and periodic monitoring of serum potassium, creatinine and uric acid levels is recommended. Thiazide diuretic-associated azotaemia may occur in patients with impaired renal function. If progressive renal impairment becomes evident, careful reappraisal of therapy is necessary, with consideration given to discontinuing diuretic therapy.
Olmetec D 40 mg/12.5 mg and 40 mg/25 mg is therefore contraindicated in all stages of renal impairment.
There is no experience of the administration of Olmetec D in patients with a recent kidney transplantation.
Dual blockade of the renin-angiotensin-aldosterone system (RAAS):
There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended.
If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.
ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.
Hepatic impairment:
There is currently no experience of olmesartan medoxomil in patients with severe hepatic impairment. In patients with moderate hepatic impairment, the maximum dose is 20 mg olmesartan medoxomil.
Furthermore, minor alterations of fluid and electrolyte balance during thiazide therapy may precipitate hepatic coma in patients with impaired hepatic function or progressive liver disease.
Therefore the use of Olmetec D 40 mg/12.5 mg and 40 mg/25 mg in patients with moderate and severe hepatic impairment, cholestasis and biliary obstruction is contraindicated. Care should be taken in patients with mild impairment.
Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy:
As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.
Primary aldosteronism:
Patients with primary aldosteronism generally will not respond to anti-hypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of Olmetec D is not recommended in such patients.
Metabolic and endocrine effects:
Thiazide therapy may impair glucose tolerance. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required. Latent diabetes mellitus may become manifest during thiazide therapy.
Increases in cholesterol and triglyceride levels are undesirable effects known to be associated with thiazide diuretic therapy.
Hyperuricaemia may occur or frank gout may be precipitated in some patients receiving thiazide therapy.
Electrolyte imbalance:
As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.
Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (including hypokalaemia, hyponatraemia and hypochloraemic alkalosis). Warning signs of fluid or electrolyte imbalance are dryness of the mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or vomiting.
The risk of hypokalaemia is greatest in patients with cirrhosis of the liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or ACTH.
Conversely, due to antagonism at the angiotensin-II receptors (AT1) through the olmesartan medoxomil component of Olmetec D hyperkalaemia may occur, especially in the presence of renal impairment and/or heart failure, and diabetes mellitus. Adequate monitoring of serum potassium in patients at risk is recommended. Potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes and other medicinal products that may increase serum potassium levels (e.g. heparin) should be co-administered cautiously with Olmetec D.
There is no evidence that olmesartan medoxomil would reduce or prevent diuretic-induced hyponatraemia. Chloride deficit is generally mild and usually does not require treatment.
Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.
Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia.
Dilutional hyponatraemia may occur in oedematous patients in hot weather.
Lithium:
As with other angiotensin II receptor antagonists, the coadministration of Olmetec D and lithium is not recommended.
Sprue-like enteropathy:
In very rare cases severe, chronic diarrhoea with substantial weight loss has been reported in patients taking olmesartan few months to years after drug initiation, possibly caused by a localized delayed hypersensitivity reaction. Intestinal biopsies of patients often demonstrated villous atrophy. If a patient develops these symptoms during treatment with olmesartan, and in the absence of other apparent etiologies, olmesartan treatment should be immediately discontinued and should not be restarted. If diarrhoea does not improve during the week after the discontinuation, further specialist (e.g. a gastro-enterologist) advice should be considered.
Acute Myopia and Secondary Angle-Closure Glaucoma:
Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.
Ethnic differences:
As with all other angiotensin II receptor antagonist containing products, the blood pressure lowering effect of Olmetec D is somewhat less in black patients than in non-black patients, possibly because of a higher prevalence of low-renin status in the black hypertensive population.
Anti-doping test:
Hydrochlorothiazide contained in this medicinal product could produce a positive analytic result in an anti-doping test.
Pregnancy:
Angiotensin II receptor antagonists should not be initiated during pregnancy. Unless continued angiotensin II receptor antagonists therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started.
Other:
As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic heart disease or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke.
Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.
Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics.
This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Olmetec D 40 mg/12.5 mg and 40 mg/25 mg has minor or moderate influence on the ability to drive and use machines. Dizziness or fatigue may occasionally occur in patients taking antihypertensive therapy, which may impair the ability to react.
Posology
Adults
The recommended dose of Olmetec D 40 mg/12.5 mg or 40 mg/25 mg is 1 tablet per day.
Olmetec D 40 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled by olmesartan medoxomil 40 mg alone.
Olmetec D 40 mg/25 mg may be administered in patients whose blood pressure is not adequately controlled on Olmetec D 40 mg/12.5 mg fixed dose combination.
For convenience, patients receiving olmesartan medoxomil and hydrochlorothiazide from separate tablets may be switched to Olmetec D 40 mg/12.5 mg and 40 mg/25 mg tablets containing the same component doses.
Olmetec D 40 mg/12.5 mg and 40 mg/25 mg can be taken with or without food.
Elderly (age 65 years or over)
In elderly people the same dosage of the combination is recommended as for adults.
Blood pressure should be closely monitored.
Renal impairment
Olmetec D is contraindicated in patients with severe renal impairment (creatinine clearance < 30 mL/min).
The maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatinine clearance of 30 - 60 mL/min) is 20 mg olmesartan medoxomil once daily, owing to limited experience of higher dosages in this patient group, and periodic monitoring is advised.
Olmetec D 40 mg/12.5 mg and 40 mg/25 mg is therefore contraindicated in all stages of renal impairment.
Hepatic impairment
Olmetec D 40 mg/12.5 mg and 40 mg/25 mg should be used with caution in patients with mild hepatic impairment. Close monitoring of blood pressure and renal function is advised in hepatically-impaired patients who are receiving diuretics and/or other antihypertensive agents. In patients with moderate hepatic impairment, an initial dose of 10 mg olmesartan medoxomil once daily is recommended and the maximum dose should not exceed 20 mg once daily. There is no experience of olmesartan medoxomil in patients with severe hepatic impairment. Olmetec D 40 mg/12.5 mg and 40 mg/25 mg therefore should not be used in patients with moderate and severe hepatic impairment , as well as in cholestasis and biliary obstruction.
Paediatric population
The safety and efficacy of Olmetec D 40 mg/12.5 mg and 40 mg/25 mg in children and adolescents below 18 years has not been established. No data are available.
Method of administration
The tablet should be swallowed with a sufficient amount of fluid (e.g. one glass of water). The tablet should not be chewed and should be taken at the same time each day.
No special requirements.
